|
**Overview**: Allergy Phadiatop Adult Panel**Introduction**: The Allergy Phadiatop Adult Panel is a diagnostic tool designed to screen for inhalant allergies in adults using serum samples. In India, Phadiatop (mixed inhalant allergens) positivity is high in allergic rhinitis and asthma patients (~50-70 percent in symptomatic cohorts), reflecting dominant indoor allergens like dust mite and outdoor pollen/mold. Allergic rhinitis affects ~20-30 percent of adults, with asthma contributing to 37.5 million cases. Symptoms include persistent sneezing, nasal congestion, wheezing, and eye irritation, exacerbated by urban pollution and seasonal changes. High morbidity from underdiagnosis in working adults, limited specialist access in rural areas, and delayed management leading to chronic issues. Per immunology practices aligned with ICMR guidelines, the test employs immunoassay for Phadiatop mix analysis over 1-2 days with high sensitivity/specificity, valuable as a broad screening tool for inhalant atopy. This diagnostic falls under allergy screening and targets adults with suspected inhalant allergies, addressing accurate detection to guide further specific testing and treatment. With morbidity elevated due to underdiagnosis, the test supports public health efforts by enabling early identification, facilitating management, and reducing chronic respiratory burden. Its serum-based approach ensures reliable detection.**Other Names**: Phadiatop Adult Pnl.**FDA Status**: FDA approved, CLIA certified for immunology, compliant with 2025 standards.**Historical Milestone**: Developed as a screening mix; in India, widely used in respiratory clinics for inhalant atopy detection.**Purpose**: The test screens for 1 parameter (Phadiatop inhalant mix) to guide assessment of inhalant allergy, identify atopy, inform further specific testing and treatment.**Test Parameters**: 1. Phadiatop (Inhalant Allergens Mix).**Pretest Condition**: No fasting required; patients should report persistent rhinitis or asthma symptoms.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on symptoms, exposures (dust, pollen, mold), family atopy history.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated inhalant allergies including chronic respiratory issues, benefits of early detection, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store kits according to manufacturer specifications to ensure reliability.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or concurrent infections can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Abnormal results indicate possible inhalant atopy, necessitating further investigation like specialist consultation or specific allergen testing. Normal results may require follow-up if symptoms persist.**Specialist Consultation**: Allergists or pulmonologists should be consulted for case management, treatment planning, and coordination with health programs.**Additional Supporting Tests**: Specific IgE panels or spirometry for confirmation.**Test Limitations**: The test may produce false negatives in low exposure or false positives in asymptomatic sensitization, requiring a comprehensive diagnostic approach that includes clinical correlation.**References**: ICMR Allergy Guidelines 2023, Indian Journal Respiratory Medicine 2024. |
